Ampullary Cancer Clinical Trials (2026): 12 Recruiting Interventional Studies

Last updated: March 10, 2026

Current Clinical Trial Landscape

About ampullary cancer:

Ampullary cancer arises from the ampulla of Vater where the bile duct and pancreatic duct meet the duodenum. It has better prognosis than pancreatic cancer due to earlier symptom presentation (jaundice). Can have intestinal or pancreatobiliary histology with different molecular profiles.

Active research areas in 2026:

Standard of care: Pancreaticoduodenectomy (Whipple procedure) for resectable disease. Adjuvant chemotherapy (gemcitabine or capecitabine). For metastatic: treated similar to biliary tract cancer.

Recruiting Trials by Treatment Setting

Neoadjuvant / Resectable

Before or instead of upfront surgery:

Metastatic / Advanced

For unresectable or metastatic disease:

Trials by Treatment Approach

Immunotherapy

Checkpoint inhibitors for biomarker-selected patients:

KRAS-Targeted Therapy

KRAS mutations are common in ampullary cancer:

Targeted Therapy

Surgical Approaches

Chemotherapy Optimization

View all 12 ampullary cancer trials on ClinicalTrials.gov →

Trial listings from ClinicalTrials.gov. Page summaries generated by AI and may contain errors. Always verify with your healthcare provider.

Find Ampullary Cancer Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific histology and treatment history.

Find Matching Trials